Credit Suisse Ag Harmony Biosciences Holdings, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 38,418 shares of HRMY stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,418

Previous 38,418 -0.0%

Holding current value

$1.33 Million

Previous $1.24 Million 4.03%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$19.2 - $33.78 $34,099 - $59,993	-1,776 Reduced 4.42%	38,418 $1.24 Million
Q3 2023 Nov 13, 2023	BUY	$31.89 - $39.03 $51,502 - $63,033	1,615 Added 4.19%	40,194 $1.32 Million
Q2 2023 Aug 11, 2023	BUY	$30.5 - $37.4 $541,924 - $664,523	17,768 Added 85.38%	38,579 $1.36 Million
Q1 2023 May 10, 2023	BUY	$30.8 - $53.92 $14,784 - $25,881	480 Added 2.36%	20,811 $679,000
Q4 2022 Feb 13, 2023	SELL	$45.4 - $60.91 $2,270 - $3,045	-50 Reduced 0.25%	20,331 $1.12 Million
Q3 2022 Nov 10, 2022	BUY	$42.06 - $55.45 $97,537 - $128,588	2,319 Added 12.84%	20,381 $901,000
Q2 2022 Aug 12, 2022	BUY	$33.54 - $52.15 $208,082 - $323,538	6,204 Added 52.32%	18,062 $880,000
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $45,302 - $69,894	1,367 Added 13.03%	11,858 $577,000
Q4 2021 Feb 14, 2022	BUY	$34.09 - $43.91 $38,214 - $49,223	1,121 Added 11.96%	10,491 $447,000
Q3 2021 Nov 12, 2021	BUY	$25.68 - $38.61 $4,031 - $6,061	157 Added 1.7%	9,370 $359,000
Q2 2021 Aug 16, 2021	BUY	$25.96 - $33.44 $239,169 - $308,082	9,213 New	9,213 $260,000

Others Institutions Holding HRMY

# of Institutions

242

Shares Held

45.1M

Call Options Held

108K

Put Options Held

49.2K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.05B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account